nutch_noindex
CANCELAR
COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >

/nutch_noindex

Silvina Pugliese, MD

  • No hay imagen

Especialidades médicas y/o especialidades quirúrgicas

Dermatology

Trabajo y educación

Educación

Boston University School of Medicine, Boston, MA, 5/15/2010

Primeros años de residencia

Stanford University, Stanford, CA 94305, 6/24/2011

Últimos años de residencia

Loma Linda University, Loma Linda, CA 92354, 6/30/2014

Certificado(s) de especialidad

Dermatology, American Board of Dermatology

Todo Publicaciones

Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients CLINICAL CASE REPORTS Wang, J. Y., Tabata, M. M., Pugliese, S., Phillips, D., Kim, J., Weng, W., Kwong, B. Y. 2019

View details for DOI 10.1002/ccr3.2458

View details for Web of Science ID 000496342800001

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption JAMA DERMATOLOGY Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., Kwong, B. Y. 2019; 155 (7): 84850
Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA dermatology Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., Kwong, B. Y. 2019

View details for PubMedID 31017625

Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy. JAAD case reports Hirotsu, K., Chiou, A. S., Chiang, A., Kim, J., Kwong, B. Y., Pugliese, S. 2017; 3 (5): 4046

View details for PubMedID 28884139

Cutaneous Complications of Targeted Melanoma Therapy (17, 57, 2016) CURRENT TREATMENT OPTIONS IN ONCOLOGY de Golian, E., Kwong, B. Y., Swetter, S. M., Pugliese, S. B. 2016; 17 (12): 63

View details for PubMedID 27817056

Cutaneous Complications of Targeted Melanoma Therapy. Current treatment options in oncology de Golian, E., Kwong, B. Y., Swetter, S. M., Pugliese, S. B. 2016; 17 (11): 57-?

Abstract

The landscape of advanced and metastatic melanoma therapy has shifted dramatically in recent years. Since 2011, eight drugs (ipilimumab, vemurafenib, dabrafenib, trametinib, cometinib, pembrolizumab, nivolumab, and talimogene laherparepvec) have received FDA approval for the treatment of advanced or metastatic melanoma, including combination regimens of both small molecule kinase and immune checkpoint inhibitors. These therapies have revolutionized the management of unresectable regional nodal and distant melanoma, providing hope of extended survival to patients. As the use of novel agents has increased, so have the cutaneous toxicities associated with these medications. While most skin reactions are low-grade and can be managed conservatively with topical therapies, malignant lesions and more serious or life-threatening drug reactions can arise during therapy, requiring prompt dermatologic recognition and treatment in order to improve patient outcome. Given the survival benefit attributed to these new agents, treating skin toxicity and maintaining patient quality of life is of paramount importance. Oncologists should be aware of the common cutaneous toxicities associated with these medications and should be encouraged to involve dermatologists in the collaborative care of advanced melanoma patients. Close communication between oncologists and dermatologists can help to avoid unnecessary dose reduction or treatment discontinuation and identify situations when treatment cessation is truly warranted.

View details for DOI 10.1007/s11864-016-0434-0

View details for PubMedID 27645330

Management of Dermatologic Complications of Lung Cancer Therapies. Current treatment options in oncology Pugliese, S. B., Neal, J. W., Kwong, B. Y. 2015; 16 (10): 50-?

Abstract

In recent years, oncogene-directed targeted agents and immunotherapies have expanded the treatment armamentarium for advanced lung cancer and, in particular, non-small cell lung cancer (NSCLC). Along with extended survival, these agents are accompanied by a host of cutaneous complications that affect the skin, hair, and nails. These skin complications range from the well-characterized papulopustular (acneiform) eruption of the epidermal growth factor receptor (EGFR) inhibitors to the emerging characterization of lichenoid skin eruptions seen during treatment with antibodies targeting the programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand (PD-L1). When promptly recognized and accurately diagnosed, most cutaneous adverse events can be managed with supportive treatments, avoiding the need to interrupt antitumor therapy. Furthermore, preemptive management of skin problems can lead to significantly decreased severity of many cutaneous complications of these therapies. We encourage close collaboration between dermatologists and oncologists to better characterize cutaneous toxicity, select appropriate management, and avoid unnecessary dose reduction or discontinuation while simultaneously improving patient quality of life.

View details for DOI 10.1007/s11864-015-0368-y

View details for PubMedID 26338208

Management of Dermatologic Complications of Lung Cancer Therapies. Current treatment options in oncology Pugliese, S. B., Neal, J. W., Kwong, B. Y. 2015; 16 (10): 368-?

Abstract

In recent years, oncogene-directed targeted agents and immunotherapies have expanded the treatment armamentarium for advanced lung cancer and, in particular, non-small cell lung cancer (NSCLC). Along with extended survival, these agents are accompanied by a host of cutaneous complications that affect the skin, hair, and nails. These skin complications range from the well-characterized papulopustular (acneiform) eruption of the epidermal growth factor receptor (EGFR) inhibitors to the emerging characterization of lichenoid skin eruptions seen during treatment with antibodies targeting the programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand (PD-L1). When promptly recognized and accurately diagnosed, most cutaneous adverse events can be managed with supportive treatments, avoiding the need to interrupt antitumor therapy. Furthermore, preemptive management of skin problems can lead to significantly decreased severity of many cutaneous complications of these therapies. We encourage close collaboration between dermatologists and oncologists to better characterize cutaneous toxicity, select appropriate management, and avoid unnecessary dose reduction or discontinuation while simultaneously improving patient quality of life.

View details for DOI 10.1007/s11864-015-0368-y

View details for PubMedID 26338208

Cosmetic benefits of natural ingredients. Journal of drugs in dermatology : JDD Bowe, W. P., Pugliese, S. 2014; 13 (9): 102125

Abstract

Photoaging is a leading concern for patients and many of these patients will express a desire to utilize natural ingredients as treatment. Mushrooms, feverfew, green tea, licorice, olive oil, soy, and coffee berry have been shown to have antioxidant properties and may play a role in the treatment and prevention of photoaging. In this manuscript, the most recent select basic science and clinical studies examining the mechanisms and efficacy of these ingredients will be discussed.

J Drugs Dermatol. 2014;13(9):1021-1025.

View details for PubMedID 25226001

Favre-Racouchot Syndrome Acneiform Eruptions in Dermatology Zeichner, J. A., Pugliese , S., Smith, A., Epstein, R., Torres, A. Springer Publishing. 2013: 253257

Abstract

To demonstrate the efficacy of the UVAR XTS Photopheresis System and evaluate health-related quality of life in patients with early-stage mycosis fungoides (MF).Extracorporeal photopheresis was administered 2 days every 4 weeks for 6 months. Patients with partial responses by skin weighted assessment continued for 6 months; nonresponders added oral bexarotene and/or interferon . Health-related quality of life was assessed at baseline and every 3 months with 3 validated tools.Nineteen patients with early-stage MF (7 men, 12 women; 16 white, 3 African Americans) with median age of 63.5 years (range, 46-85 years) participated. Their stages were IA (n = 3), IB (n = 14), and IIA (n = 2). The overall response rate for extracorporeal photopheresis (ECP) alone, was 42% (8/19; including 7 partial response, 1 complete response), with a median of 12 ECP sessions (range, 3-32) given over a median of 12 months (3-32 months) and with an overall duration of response of 6.5 months (range, 1-48 months). Seven patients with stable disease at 3 months received additional bexarotene (3/5; 1 complete response) or bexarotene plus interferon (1/2), and 4 (57%) of 7 responded. Treatment-related adverse effects were limited to those expected with interferon (fatigue, nausea, vomiting, and diarrhea), or with hypertriglyceridemia and bexarotene. Trends in health-related quality of life indicated an improvement in emotional scores over time.ECP is effective for patients with early-stage MF alone or in combination with biologic response modifiers with low toxicity and improved quality of life.

View details for DOI 10.1016/j.dml.2011.03.003

View details for Web of Science ID 000291235900006

View details for PubMedID 21575927

Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Talpur, R., Demierre, M. F., Geskin, L., Baron, E., Pugliese, S., Eubank, K., Zic, J. A., Miller, D. R., Tharp, M., Bohjanen, K., Duvic, M. 2011; 11 (2): 219-227
DermHub: A comprehensive dermatology-focused patient education resource and social community Hagele, T., Cheng, C., Kvedar, J., Konda, S., Pugliese, S. MOSBY-ELSEVIER. 2011: AB78

View details for Web of Science ID 000276813500028

View details for PubMedID 20404248

Adverse Reaction to Cutaneous Injection of Contents From a Vitamin E Liquid-Containing Capsule ARCHIVES OF DERMATOLOGY Pugliese, S., Yaar, R., Al-Dawsari, N., Goldberg, L. J., Garg, A. 2010; 146 (4): 454-455